MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, June 26, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced the closing of its previously announced public offering of an aggregate of 4,000,000 of the Company’s ordinary shares and accompanying warrants to purchase up to 4,000,000 of the Company’s ordinary shares, at a combined public offe ...

MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, June 25, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced the pricing of a public offering of an aggregate of 4,000,000 of the Company’s ordinary shares and accompanying warrants to purchase up to 4,000,000 of the Company’s ordinary shares, at a combined public offering price of $0.65 per ...

Decision at the highest levels of appeal in the Medicare process establishes medical necessity of the ReWalk Exoskeleton for enabling paralyzed individuals to stand and walk in everyday environments.MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, June 24, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd., (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced the recent ruling by an Adminis ...

纪要涉及的公司 Lifeword Limited 纪要提到的核心观点和论据 1. **公司未来增长定位** - 拥有领先创新技术，可改变生活且能商业化 [4] - 报销覆盖范围扩大，产品使用后可获得支付 [5] - 具备在诊所和家庭市场推广产品的能力 [5] - 过去十二个月的变革使运营亏损减少，预计2026年2月19日实现盈利 [6] 2. **公司成就** - 多项行业首创，如获得5 - 10k de novo和CE Mark覆盖、采用NASA衍生应用、在德国医疗设备目录中获得外骨骼产品 listing、实现个人外骨骼产品的医疗保险覆盖 [7][8][9] 3. **主要产品介绍** - **ReWalk外骨骼** - 特点：提供前所未有的自由，可在多种地面行走；自然步态，行走方式与正常人相似；坚固耐用，有良好服务网络；有活跃社区促进市场发展 [13][14] - 工作原理：通过鞋垫、带电机和微处理器的管状结构、软件组件、电池和传感器实现行走控制，续航四小时 [16][17] - 最新版本优势：更易控制、行走更智能、运动更平滑、动力更强、贴合个人身体需求 [19][20][21][22] - 健康益处：改善肠道功能、减少痉挛、减轻疼痛、促进心血管健康、改善身体成分 [24][25][26] - 报销情况：美国退伍军人和医疗保险覆盖人群可使用，一家顶级保险公司开始支付，扩大了商业市场和工人补偿保险合作 [29][30] - 市场规模：美国约有近30万潜在用户，德国约7.5万，符合临床标准且有报销途径的美国约1.5万，德国约2000，总计约1.7万 [33][34] - **AlterG反重力系统** - 工作方式：患者穿上特制短裤，通过半月形空气装置按预设减轻体重，进出方便，设备校准精确 [35][36] - 市场情况：全球约有6000台，美国可目标诊所约1.4万，德国约3500，全球约4万，有良好增长潜力，去年推出的新产品Neo和Neo plus提升了利润率 [36][38][40] - **MyoCycle FES功能性电刺激自行车** - 使用方式：用户将轮椅连接到设备，连接电极即可使用，有诊所和家用版本 [40][41] - 功效：预防萎缩、减少痉挛、增加血液流动和关节活动范围，与ReWalk互补 [41][42] - **ReStore外骨骼套装** - 适用人群：主要针对中风患者 [43] - 工作原理：通过鞋垫、小腿装置、电机和电池组实现脚趾和脚跟的抬起，帮助患者重新学习行走 [44] - 效果：在随机试验中显示出有效性，有助于实现对称推进和肢体前进 [45] 4. **财务进展** - 从单一产品公司发展为多产品公司，预计今年收入达2800 - 3000万美元 [47] - 随着收入增长和产品组合增加，毛利率预计扩大 [47][48] - 通过收购AlterG实现协同效应和运营效率提升，成本结构相对固定 [48] 5. **报销流程进展** - 去年1月被纳入一次性付款类别，4月产品定价约9.1 - 9.3万美元 [53] - 初期报销处理效率低，近期与CMS沟通取得进展，预计缩短提交、审批和付款周期 [54][55] 6. **寻找合格候选人的方式** - 社交媒体推广，获取大量潜在患者，但转化率较低 [59] - 医生推荐，转化率较高，需加强对医生的教育 [60] - 与大型机构合作，举办诊所日和试验活动 [61] 7. **毛利率增长因素** - 产品组合变化，增加ReWalk的支付方有助于提高毛利率 [64] - 规模效应，随着收入增长，可更高效利用资源和采购零部件 [65][66] 8. **产品协同效应** - 使用同一销售、服务、培训、支付和管理团队 [67] - 部分产品针对诊所市场，部分产品可送回家用，ReWalk的潜在患者也是MyoCycle的潜在患者 [68][69] 9. **现金流盈亏平衡目标** - 预计收入达到4000 - 4500万美元可实现现金流和运营利润盈亏平衡，2026年有望实现 [70][71] 其他重要但是可能被忽略的内容 - AlterG产品在新罕布什尔州通过合同制造商生产，MyoCycle产品在佛罗里达州生产且零部件主要来自美国，ReWalk产品在以色列生产，残疾人产品协议使ReWalk最终产品一般可免关税，部分零部件可能受影响 [72]

此前在 美敦力（2004–2023） 任职近20年 ，最终担任美洲地区副总裁 ，主导糖尿病家庭护理业务的支付策略与市场准入。其领导的跨职能团队涵盖 销售、临床支 持、健康经济学、报销、客户服务与营销 等关键部门，具备丰富的跨区域管理经验。 | 思宇年度活动回顾： 首届全球眼科大会 | 首届全球骨科大会 | 首届全球心血管大会 | | | | | | --- | --- | --- | --- | --- | --- | --- | | 即将召开： | | | | | | | | 2025年6月12日，首届全球医美科技大会 | | | | | | | | 2025年7月17日，第二届全球医疗科技大会 | | | | | | | | 2025年9月4-5日，第三届全球手术机器人大会 | | | | | | | | 2025年5月19日 ， 康复护理公司 | Lifeward（纳斯达克代码：LFWD） | 宣布任命 | 前美敦力美洲区副总裁Mark Grant 为公司新任 | 总裁兼首席执行官 | ，自 | 2025年6月2日 | | 起正式生效。此次任命标志着Lifeward进入从技术验证向商业增长过渡的关键阶段 ...

Industry veteran brings 30 years of commercial leadership experienceMARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, May 19, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that Mark Grant has been appointed as the Company’s new President and Chief Executive Officer, effective June 2, 2025. Larry Jasinski, Lifeward’s outgoing CEO, will ...

Lifeward (LFWD) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $0.73 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -39.39%. A quarter ago, it was expected that this maker of wearable robotic exoskeletons that help paralyzed patients walk would post a loss of $0.20 per share when it actually produced a loss of $0.38, delivering a surprise of - ...

Lifeward (LFWD) Q1 2025 Earnings Call May 15, 2025 08:30 AM ET Company Participants Mike Lawless - CFOLarry Jasinski - CEOBen Haynor - Managing Director Conference Call Participants Yale Jen - Senior Managing Director & Senior Biotech AnalystSwayampakula Ramakanth - Managing Director & Senior Equity Analyst Operator Good day, and welcome to the Q1 twenty twenty five LifeForward, Inc. Earnings Conference Call. All participants will be in listen only mode. Please note this event is being recorded. I would now ...

Lifeward (LFWD) Q1 2025 Earnings Call May 15, 2025 08:30 AM ET Speaker0 Good day, and welcome to the Q1 twenty twenty five LifeForward, Inc. Earnings Conference Call. All participants will be in listen only mode. Please note this event is being recorded. I would now like to turn the conference over to Mike Lawless, Chief Financial Officer. Please go ahead. Speaker1 Thank you, Cindy. Good morning and welcome to LifeWorks first quarter twenty twenty five earnings call. I'm Mike Laulis, LifeWorks Chief Financi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36612 Lifeward Ltd. (Exact name of registrant as specified in charter) | Israel | | --- | | Not applicable | (State or other jurisdiction ...